INLYTA Drug Patent Profile

Which patents cover Inlyta, and when can generic versions of Inlyta launch?

Inlyta is a drug marketed by Pf Prism Cv and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-seven patent family members in thirty countries.

The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the axitinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Inlyta

Inlyta was eligible for patent challenges on January 27, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 14, 2031. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (axitinib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for INLYTA

International Patents:	97
US Patents:	4
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INLYTA

Paragraph IV (Patent) Challenges for INLYTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INLYTA	Tablets	axitinib	1 mg and 5 mg	202324	1	2018-02-23

US Patents and Regulatory Information for INLYTA

INLYTA is protected by four US patents.

This potential generic entry date is based on patent 8,791,140.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-001	Jan 27, 2012		RX	Yes	No	8,791,140*PED				Y
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-002	Jan 27, 2012		RX	Yes	Yes	10,869,924*PED				Y
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-001	Jan 27, 2012		RX	Yes	No	10,570,202*PED				Y

International Patents for INLYTA

When does loss-of-exclusivity occur for INLYTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Cyprus

Denmark

European Patent Office

Finland

Hong Kong

Israel

Japan

Mexico

New Zealand

Poland

Portugal

Russian Federation

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INLYTA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015214390
Brazil	112016017256
Canada	2937521

Supplementary Protection Certificates for INLYTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1218348	C01218348/01	Switzerland		FORMER OWNER: AGOURON PHARMACEUTICALS, INC., US
1218348	CA 2013 00010	Denmark
1218348	PA2013003	Lithuania		PRODUCT NAME: AXITINIBUM; REGISTRATION NO/DATE: EU/1/12/777/001 - EU/1/12/777/006 20120903

Last updated: July 12, 2026

Inlyta (axitinib) Investment Scenario and Patent/Regulatory Fundamentals Analysis

Executive summary

Inlyta (axitinib) is a branded oral VEGFR tyrosine kinase inhibitor with no immediate US “clean generics” path limited by active Orange Book exclusivities beyond typical small-molecule patent expiry patterns. The investment case depends less on near-term US regulatory exclusivity and more on: (1) competitive share erosion versus newer VEGF inhibitors and immunotherapy backbones, (2) durability of Axitinib combination revenue, and (3) the pace of biosimilar/generic substitution for competing oncology TKIs across payer formularies. On the IP front, axitinib’s patent estate is largely expected to be mature, shifting the focus to line-extension patents (formulations, polymorphs, manufacturing) and any residual method-of-use claims tied to approved combinations.

What is Inlyta (axitinib) used for, and what are the current market drivers?

Featured answer: Inlyta is used in RCC (renal cell carcinoma) settings and has historically been positioned in combination regimens with PD-1/PD-L1 checkpoint inhibitors and with other systemic therapy sequences.

RCC label and regimen mix that drives revenue

Core economic drivers

• Combination platform effect: axitinib is often paired with checkpoint inhibitors, turning a TKI into a backbone therapy.
• Sequence dependence: market outcomes are influenced by whether axitinib is used earlier in the metastatic pathway or after progression.
• Payer preference and step edits: formularies increasingly prefer regimens with superior efficacy and manageable toxicity profiles.

Key competitive set (high level)

Axitinib competes with:

• Other VEGFR TKIs (e.g., cabozantinib, lenvatinib, tivozanib depending on line and geography)
• Checkpoint inhibitor combinations that can reduce reliance on older TKIs when payers tighten step therapy

What patents protect Inlyta (axitinib) in the US, and what is the expiration map?

Featured answer: Inlyta’s US IP protection is expected to be dominated by late-cycle small-molecule composition and method-of-use patents, with additional coverage potential in formulation and manufacturing. Any remaining “last-mile” coverage typically limits generic launch timing and not initial combination adoption.

How to read the Inlyta US patent estate for investment

For an investment model, categorize patents into:

• Composition of matter (active ingredient, salts, polymorphs)
• Formulation and dosage (tablet/pellet/crystalline dispersion, excipients, particle size)
• Method-of-use (treatment of RCC, combinations with immunotherapy)
• Manufacturing/process patents (crystal formation, polymorph control, process yields)

Investment implication

• If composition-of-matter is expired, generic entry becomes feasible, but method-of-use and formulation can still create partial barriers depending on Paragraph IV posture and FDA labeling.

US expiration mapping and residual risk

Because an accurate expiration date requires line-item Orange Book patent numbers and expiration fields, this analysis does not enumerate specific patent expiry dates here.

When does Inlyta lose exclusivity in the US, and how long do exclusivities last?

Featured answer: Small-molecule drugs typically rely on patent term rather than FDA-granted exclusivity blocks that create multi-year statutory market protection. For Inlyta, the practical “exclusivity” timeline is dominated by:

• Patent expiration and any pediatric patent term adjustments (if applicable)
• Possible remaining unexpired patents listed in the Orange Book that can prevent generic approval or trigger litigation

Paragraph IV timing impact

If a generic files a Paragraph IV ANDA, settlement timing and “trigger” dates often determine whether branded revenues compress rapidly or remain resilient.

How many Orange Book patents are listed for Inlyta, and what are the key coverage categories?

Featured answer: Orange Book status determines generic exposure risk, but the exact count and category split requires the current Orange Book listing dataset.

Typical Orange Book structure for oncology TKIs

Most branded TKIs show:

• Several composition/method patents
• A smaller number of formulation/solid-state and process patents
• At least one patent tied to a combination regimen or an approved indication (method-of-use)

Which companies are challenging Inlyta with Paragraph IV ANDAs, and what does that do to generic entry risk?

Featured answer: The generic threat for Inlyta is determined by the number and timing of Paragraph IV filings against Orange Book-listed patents, plus the likelihood of successful “carve-outs” via labeling.

Investment-facing risk framework

• High risk: multiple ANDA filers with near-identical carve-out positions and no adverse injunction outcomes.
• Medium risk: limited filings with settlements that delay launch.
• Low risk: no active challenges, or challenges that target patents nearing expiry.

What patent litigation affects Inlyta (axitinib), and what settlements matter commercially?

Featured answer: Litigation affects commercial outcomes mainly through (1) launch delay from automatic 30-month stays, (2) settlement-based “pay-for-delay” style delays (where applicable), and (3) scope-of-label restrictions that preserve branded positioning.

Commercial effect of settlement terms

For investment modeling, settlements matter more for:

• Launch date calendar risk
• Label scope (what “indications” and “subpopulations” generics can reference)
• Any authorized generic arrangements

What FDA status applies to Inlyta (axitinib), and is it approved under any special exclusivity programs?

Featured answer: Inlyta is an FDA-approved small-molecule oncology product. For exclusivity, the relevant investor question is whether any marketing exclusivity beyond the standard 3/5-year framework applies to a specific supplement that expands indications. That can extend “effective exclusivity” even after core composition patents expire.

Label expansion risk

When brands add indications, the FDA exclusivity attached to new clinical data can shift generic incentives and timing of carve-outs.

What formulations are protected for Inlyta, and do they meaningfully block generics?

Featured answer: For oncology TKIs, solid-state/formulation patents rarely block all generic entry unless they force bioequivalence testing to avoid infringement or unless specific crystalline form or manufacturing steps are patented.

Where formulation patents matter

• Narrowly defined particle size or solid-state form
• Specific excipient system and manufacturing process
• Proprietary tablet characteristics tied to dissolution profile

How strong is the patent estate for Inlyta (axitinib), and what is the infringement “coverage depth”?

Featured answer: For mature small-molecule oncology assets, the estate strength usually degrades over time with composition claims expiring first. What remains tends to be harder to enforce broadly because generic entry can be achieved through:

• Design-around for formulation
• Label carve-outs for method-of-use
• Carve-out ANDA approvals that avoid the infringed indication

Investment conclusion on IP strength

The investment case should treat the residual patent estate as a timing tool rather than a long-term moat, unless the remaining patents are clearly tied to core approved indications without viable carve-outs.

How does Inlyta compare with competing VEGFR TKIs (cabozantinib, lenvatinib, tivozanib) on exclusivity and patent/entry risk?

Featured answer: Competitive advantage shifts based on two axes:

• Clinical positioning and payer contracting
• Rapid generic encroachment for brands with earlier patent expiry than peers

Practical comparison for investors

• If axitinib’s practical barriers are weaker than peers, expect faster price pressure in later lines where payers prefer cost.
• If axitinib retains strong combination contracting, it can maintain share longer even under generic pressure.

What generic launch scenarios exist for Inlyta, and how would they impact revenue?

Featured answer: Revenue compression scenarios depend on how quickly generic entrants can launch with labeling that preserves the branded indication mix.

Scenario set for investment models

Scenario A: “Clean” launch

• Generic can reference key indications without carve-outs.
• Revenue declines rapidly as wholesalers and PBMs switch.

Scenario B: Carve-out launch

• Generic is limited to sub-indications that preserve branded share.
• Revenue erosion is slower; brand retains dominant combination position.

Scenario C: Litigation-driven delay

• Launch is postponed beyond next fiscal periods.
• Price pressure arrives later but is not eliminated.

KPI expectations investors should tie to the scenarios

• Net price and contract discounts
• Share in metastatic RCC combination regimens
• Channel inventory dynamics around launch windows
• Net revenue mix changes by line of therapy

What commercialization fundamentals support an Inlyta investment thesis despite generic pressure?

Featured answer: For mature oncology brands, commercialization fundamentals matter more than statutory exclusivity.

Key pillars

• Contracting and tendering: large payer contracts can preserve a branded share longer than expected.
• Prescriber inertia in combination regimens: once stabilized in a protocol, switching can lag.
• Adverse event manageability: dosing consistency and clinician familiarity affect adherence.

What are the core risks to an Inlyta investment case (regulatory, IP, and competitive)?

Featured answer: Primary risks are share loss from competition, patent-based timing slips that accelerate generic adoption, and payer renegotiation that shifts to lower cost alternatives.

Risk map

• Patent and litigation: adverse outcomes that narrow barriers to ANDA approval or remove delay.
• Regulatory: label changes that broaden or narrow the economic footprint available to generics.
• Competitive: newer combination regimens displacing TKI backbones.

Key Takeaways

• Inlyta’s investment case is primarily driven by RCC regimen share durability and payer contracting, not ongoing statutory exclusivity.
• Patent protection is likely mature; the practical investor lens is residual Orange Book-listed patents that affect Paragraph IV outcomes and labeling carve-outs.
• Generic entry risk is determined by ANDA filing cadence, settlement structures, and whether generics can preserve broad indication coverage.
• Competitive dynamics in RCC combinations will shape revenue more than incremental patent tail, unless residual IP creates real timing leverage.

FAQs

1. How do ANDA Paragraph IV “carve-outs” for Inlyta affect real-world prescribing and payer switching?
2. What is the most relevant Orange Book patent category for blocking generics of axitinib tablets?
3. Does Inlyta face higher biosimilar risk, or is it purely a small-molecule generic/ANDA risk profile?
4. What tender and contracting mechanisms in oncology drive the speed of branded-to-generic switching after launch?
5. How do RCC line-of-therapy trends change the economics of axitinib-based combination regimens?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Inlyta/axitinib listing). U.S. Food and Drug Administration.
2. FDA: Drug Approval Package for Inlyta (axitinib). U.S. Food and Drug Administration.
3. Hatch-Waxman Act framework: 21 U.S.C. § 355(j) (Paragraph IV ANDA provisions). U.S. Congress.